Clinical trial
A Perspective and Multicenter Phase II Trial of Tirelizumab Combined With R2-ICE Regimen (Rituximab, Lenalidomide, Ifosfamide, Carboplatin, Etoposide) in the Treatment of Refractory or Relapse DLBCL or HGBL
NCT05050630 is registered in ClinicalTrials.gov with Affiliated Hospital to Academy of Military Medical Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Perspective and Multicenter Phase II Trial of Tirelizumab Combined With R2-ICE Regimen (Rituximab, Lenalidomide, Ifosfamide, Carboplatin, Etoposide) in the Treatment of Refractory or Relapse DLBCL or HGBL
- Lead sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- August 1, 2021
- Completion date
- July 30, 2023
- Enrollment
- 73 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
age range ≥16 years, gender unlimited, at least one positive lesion according to the 2014 lugano criteria for hodgkin's and non-hodgkin's lymphoma, ecog physical status score is 0-3, histopathology confirmed diffuse large b-cell lymphoma or high-grade b-cell lymphoma, received prior first-line chemotherapy for dlbcl or hgbl, failed to reach cr for four cycles, or relapsed, the researchers judged that life expectancy was at least three months, understand and voluntarily sign written informed consent